Safety of glucocorticoids in rheumatoid arthritis: Evidence from recent clinical trials

NeuroImmunoModulation

Volumn 22, Issue , 2014, Pages 57-65

  Santiago, Tânia ^a   Da Silva, José António P ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Glucocorticoids; Randomized controlled trials; Review; Rheumatoid arthritis; Safety; Toxicity

Indexed keywords

CALCIUM; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GLUCOSE; GOLD; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; VITAMIN D; ANTIASTHMATIC AGENT;

ARTICLE; BONE DENSITY; BONE NECROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CATARACT; CLINICAL COMPETENCE; DIABETES MELLITUS; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ERYSIPELAS; EVIDENCE BASED MEDICINE; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INFECTION; KNOWLEDGE; LOW DRUG DOSE; MEDICATION COMPLIANCE; MEDLINE; MENTAL DISEASE; META ANALYSIS; METHODOLOGY; OBSERVATIONAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; PROSPECTIVE STUDY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SIDE EFFECT; SPINE FRACTURE; STANDARD; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL (TOPIC); FEMALE; MALE; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; TREATMENT OUTCOME;

EID: 84908569407     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000362726     Document Type: Article

References (35)

1. Jacobs JW: Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies. Rheumatology (Oxford) 2012; 51(suppl 4):iv27-iv33.
2. Jacobs JW, van Everdingen AA, Verstappen SM, Bijlsma JW: Follow-up radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 2006; 54: 1422-1428.
3. Kirwan JR, Bijlsma JW, Boers M, Shea BJ: Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007:CD006356.
4. Strand V, Simon LS: Low dose glucocorticoids in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21:S186-S190.
5. Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ: Adverse events of low- To medium-dose oral glucocorticoids in inflammatory diseases: A meta-analysis. Ann Rheum Dis 2009; 68: 1833-1838.
6. Wasko MC, Kay J, Hsia EC, Rahman MU: Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken) 2011; 63: 512-521.
7. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, de Koning EJ, Buttgereit F, Cutolo M, Capell H, Rau R, Bijlsma JW: Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65: 285-293.
8. Kirwan JR: The effect of glucocorticoids on joint destruction in rheumatoid arthritis: The arthritis and rheumatism council low-dose glucocorticoid study group. N Engl J Med 1995; 333: 142-146.
9. Hickling P, Jacoby RK, Kirwan JR, et al: Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998; 37: 930-936.
10. van Everdingen AA, Jacobs JW, Siewertsz van Reesema DR, Bijlsma JW: Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease- modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002; 136: 1-12.
11. Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, Thomson EA, Hampson R, Poon FW: Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004; 63: 797-803.
12. Wassenberg S, Rau R, Steinfeld P, Zeidler H: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, doubleblind, placebo-controlled trial. Arthritis Rheum 2005; 52: 3371-3380.
13. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I: Low-dose prednisolone in addition to the initial diseasemodifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum 2005; 52: 3360-3370.
14. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, Geurts MA, van der Werf JH, van Albada-Kuipers GA, Jahangierde Veen ZN, van der Veen MJ, Verhoef CM, Lafeber FP, Bijlsma JW: Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: A randomized trial. Ann Intern Med 2012; 156: 329-339.
15. Montecucco C, Todoerti M, Sakellariou G, Scire CA, Caporali R: Low-dose oral prednisone improves clinical and ultra sonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 2012; 14:R112.
16. Ravindran V, Rachapalli S, Choy EH: Safety of medium- To long-term glucocorticoid therapy in rheumatoid arthritis: A meta-analysis. Rheumatology (Oxford) 2009; 48: 807-811.
17. van der Goes MC, Jacobs JW, Jurgens MS, Bakker MF, van der Veen MJ, van der Werf JH, Welsing PM, Bijlsma JW: Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int 2013; 24: 1429-1436.
18. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG: Effects of low-dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis: A meta-analysis. J Investig Med 2008; 56: 1011-1018.
19. Hoes JN, van der Goes MC, van Raalte DH, van der Zijl NJ, den Uyl D, Lems WF, Lafeber FP, Jacobs JW, Welsing PM, Diamant M, Bijlsma JW: Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011; 70: 1887-1894.
20. Buttgereit F: Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis? Ann Rheum Dis 2011; 70: 1881-1883.
21. Morrison E, Crosbie D, Capell HA: Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids. Rheumatology (Oxford) 2003; 42: 1247-1250.
22. Jurgens MS, Jacobs JW, Geenen R, Bossema ER, Bakker MF, Bijlsma JW, van Albada-Kuipers IA, Ehrlich JC, Lafeber FP, Welsing PM: Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity? Arthritis Care Res (Hoboken) 2013; 65: 88-93.
23. Ruyssen-Witrand A, Fautrel B, Saraux A, Le Loet X, Pham T: Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review. Joint Bone Spine 2011; 78: 23-30.
24. Hafstrom I, Rohani M, Deneberg S, Wornert M, Jogestrand T, Frostegard J: Effects of lowdose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis: A randomized study. J Rheumatol 2007; 34: 1810-1816.
25. Engvall IL, Svensson B, Tengstrand B, Brismar K, Hafstrom I: Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Ther 2008; 10:R128.
26. Dixon WG, Suissa S, Hudson M: The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and metaanalyses. Arthritis Res Ther 2011; 13:R139.
27. Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, Cividino A, Bombardier C: Serious infections in a population based cohort of 86, 039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65: 353-361.
28. van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F, Caeyers N, Cutolo M, Da Silva JA, Guillevin L, Kirwan JR, Rovensky J, Severijns G, Webber S, Westhovens R, Bijlsma JW: Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010; 69: 1913-1919.
29. Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, Kirwan J, Kohler L, Van Riel P, Vischer T, Bijlsma JW: Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002; 61: 718-722.
30. Daly JR, Myles AB, Bacon PA, Beardwell CG, Savage O: Pituitary adrenal function during corticosteroid withdrawal in rheumatoid arthritis. Ann Rheum Dis 1967; 26: 18-25.
31. Barden N: Implication of the hypothalamicpituitary- Adrenal axis in the physiopathology of depression. J Psychiatry Neurosci 2004; 29: 185-193.
32. Pincus T, Swearingen CJ, Luta G, Sokka T: Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: A randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 2009; 68: 1715- 1720.
33. Pincus T, Sokka T, Castrejon I, Cutolo M: Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res (Hoboken) 2013; 65: 729-736.
34. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, Choy EH, Cutolo M, Da Silva JA, Esselens G, Guillevin L, Hafstrom I, Kirwan JR, Rovensky J, Russell A, Saag KG, Svensson B, Westhovens R, Zeidler H, Bijlsma JW: EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66: 1560-1567.
35. Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, Caeyers N, Cutolo M, Halliday S, Da Silva JA, Kirwan JR, Ray D, Rovensky J, Severijns G, Westhovens R, Bijlsma JW: EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013; 72: 1905-1913.